Literature DB >> 9421092

The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer.

Y Nakanishi1, J Kodama, M Yoshinouchi, K Tokumo, S Kamimura, H Okuda, T Kudo.   

Abstract

The object of this study was to clarify the association between microvessel density and clinicopathologic factors, as well as the association of angiogenic factors (vascular endothelial growth factor [VEGF] and transforming growth factor-beta [TGF-beta]) with tumor angiogenesis and patient survival in epithelial ovarian cancer. The expression of VEGF and TGF-beta was evaluated by immunohistochemical staining in 60 patients with epithelial ovarian cancer. The microvessel density, assessed by immunostaining for factor VIII-related antigen in the most neovascularized areas, varied depending on histological types but not on International Federation of Gynecology and Obstetrics stage. Patients with stage III carcinomas and positive TGF-beta had more extensive peritoneal dissemination and a worse outcome. The microvessel density of VEGF-rich and TGF-beta positive tumors was significantly higher than that of VEGF-poor and TGF-beta negative tumors. Angiogenesis appears to be an early event in epithelial ovarian cancer and may be induced differently in tumors of different histological types. The expression of VEGF and TGF-beta associates with the promotion of angiogenesis, and the expression of TGF-beta is a prognostic indicator in epithelial ovarian cancers.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9421092     DOI: 10.1097/00004347-199707000-00011

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  18 in total

1.  Functional significance of VEGFR-2 on ovarian cancer cells.

Authors:  Whitney A Spannuth; Alpa M Nick; Nicholas B Jennings; Guillermo N Armaiz-Pena; Lingegowda S Mangala; Christopher G Danes; Yvonne G Lin; William M Merritt; Premal H Thaker; Aparna A Kamat; Liz Y Han; James R Tonra; Robert L Coleman; Lee M Ellis; Anil K Sood
Journal:  Int J Cancer       Date:  2009-03-01       Impact factor: 7.396

Review 2.  Targeted therapies for gynecologic malignancies.

Authors:  Johnny Hyde; D Scott McMeekin
Journal:  Curr Treat Options Oncol       Date:  2005-03

3.  Expression of angiogenesis-related genes in ovarian carcinoma--a clinicopathologic study.

Authors:  B Davidson; I Goldberg; J Kopolovic; W H Gotlieb; V Givant-Horwitz; J M Nesland; A Berner; G Ben-Baruch; M Bryne; R Reich
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).

Authors:  John K Chan; William Brady; Bradley J Monk; Jubilee Brown; Mark S Shahin; Peter G Rose; Jae-Hoon Kim; Angeles Alvarez Secord; Joan L Walker; David M Gershenson
Journal:  Gynecol Oncol       Date:  2018-06-18       Impact factor: 5.482

5.  Clinical significance of serum transforming growth factor-beta 1 (TGF-β1) levels in patients with epithelial ovarian cancer.

Authors:  Faruk Tas; Senem Karabulut; Murat Serilmez; Rumeysa Ciftci; Derya Duranyildiz
Journal:  Tumour Biol       Date:  2013-12-06

6.  Relevant molecular markers and targets.

Authors:  Kathleen M Darcy; Russel J Schilder
Journal:  Gynecol Oncol       Date:  2006-10-10       Impact factor: 5.482

Review 7.  Angiogenesis in epithelian ovarian cancer.

Authors:  E S Bamberger; C W Perrett
Journal:  Mol Pathol       Date:  2002-12

Review 8.  Angiogenesis and ovarian cancer.

Authors:  César Gómez-Raposo; Marta Mendiola; Jorge Barriuso; Enrique Casado; David Hardisson; Andrés Redondo
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

9.  Nerve growth factor induces vascular endothelial growth factor expression in granulosa cells via a trkA receptor/mitogen-activated protein kinase-extracellularly regulated kinase 2-dependent pathway.

Authors:  Marcela Julio-Pieper; Patricia Lozada; Veronica Tapia; Margarita Vega; Cristián Miranda; David Vantman; Sergio R Ojeda; Carmen Romero
Journal:  J Clin Endocrinol Metab       Date:  2009-05-19       Impact factor: 5.958

10.  Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis.

Authors:  R Cao; H L Wu; N Veitonmäki; P Linden; J Farnebo; G Y Shi; Y Cao
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.